Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JHPCYDrugs in Pipeline
67
Phase 3 Programs
24
Upcoming Catalysts
15
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
15 upcoming, 0 past
SHR-1210
Nasopharyngeal Carcinoma
SHR-1209
Primary Hypercholesterolemia
PD-1 blocking antibody
Nasopharyngeal Carcinoma
Hetrombopag Olamine
Severe Aplastic Anemia
HRS-4642 + AG
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
SHR0302
Rheumatoid Arthritis
HR17031 injection
Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
Hetrombopag
Chemotherapy-Induced Thrombocytopenia
Pyrotinib
HER2-positive Breast Cancer
Remimazolam Tosilate
General Anesthesia
capecitabine + camrelizumab + apatinib
Breast Cancer
Camrelizumab
Hepatocellular Carcinoma
Propofol
Anesthesia for Elective Surgery Patients
apatinib
Non-Small-Cell Lung Cancer
SHR6390
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
JSKN016 Injection
Triple Negative Breast Cancer
SHR7280 tablets
Uterine Fibroids With Menorrhagia
camrelizumab combined with rivoceranib and HAIC
Potentially Resectable Hepatocellular Carcinoma
SHR-A1811
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Apatinib Mesylate
Hepatocellular Carcinoma
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Breast Cancer Invasive
SHR8554 Injection
Pain
INS068 injection
Type 2 Diabetes Mellitus
Fuzuloparib , Abiraterone acetate and Prednisone
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NALIRIFOX+Adebrelimab
Pancreatic Ductal Adenocarcinoma (PDAC)
Adebrelimab
Metastatic Colorectal Cancer
Lenvatinib
Intrahepatic Cholangiocarcinoma
HRS-4642
Pancreatic Cancer
Rezvilutamide
Prostate Cancer
Famitinib Malate
Breast Neoplasms
SHR-A2102 or/and HRS-4642
Pancreatic Cancer
Taxane Chemotherapy
HER2 + Breast Cancer
HRS-4642+AG
Pancreatic Cancer
irinotecan liposome (II) + temozolomide + fluzoparib
Ewing Sarcoma
Camrelizumab plus apatinib CohortA
Gestational Trophoblastic Neoplasia
Adebrelimab combined with Apatinib
SCLC
Camrelizumanb plus TPF
Oral Squamous Cell Carcinoma
Apatinib+IE
Effect of Drug
Neoadjuvant Chemotherapy
Esophageal Squamous Cell Carcinoma
Bupivacaine Liposome Injection
Local Analgesia Via Nerve Block
Radiation
Esophageal Neoplasms
Fluzoparib
Metastatic Castration Resistant Prostate Cancer
Herombopag
Non Severe Aplastic Anemia
EC chemotherapy
Breast Cancer Invasive
SHR-3167 Injection
Diabetes Mellitus, Type 2
HRS-4508+ Capecitabine
Solid Tumor
HRS-9190
Neuromuscular Blockade
HR19042 Capsules
IgA Nephropathy
FRSW117
Severe Hemophilia A
HRS-4508 tablet
Lung Cancer
Famitinib
Colorectal Cancer
SHR-A1811 Injection
Recurrent or Metastatic Cervical Cancer
HS-20093 for Injection
Prostate Cancer
KN046
Esophageal Squamous Cell Carcinoma
SHR-3167
Type 2 Diabetes Mellitus
SHR-4394
Prostate Cancer
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Advanced Non-small Cell Lung Cancer
HRS-9190; under Inhalational Anesthesia
Neuromuscular Blockade
Tegileridine Fumarate lnjection
Abirritation in the ICU
SHR4640 ；Febuxostat
Primary Gout and Hyperuricemia
Apatinib and Adebrelimab in Combination With chemotherapy
Intrahepatic Cholangiocarcinoma (Icc)
SHR-1210+GEMOX
Biliary Tract Cancer
entinostat
Breast Cancer
docetaxel,0xaliplatin,capecitabine
Gastric Cancer
Camrelizumab+Fluzoparib
Germline BRCA-mutated HER2-negative Breast Cancer
Epirubicin
Breast Cancer
Camrelizumab and Apatinib Plus GP
Locally Advanced Biliary Tract Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SHR-1210 | Phase 3 | Nasopharyngeal Carcinoma | - | - |
SHR-1209 | Phase 3 | Primary Hypercholesterolemia | - | - |
PD-1 blocking antibody | Phase 3 | Nasopharyngeal Carcinoma | - | - |
Hetrombopag Olamine | Phase 3 | Severe Aplastic Anemia | - | - |
HRS-4642 + AG | Phase 3 | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting | - | - |
SHR0302 | Phase 3 | Rheumatoid Arthritis | - | - |
HR17031 injection | Phase 3 | Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs | - | - |
Hetrombopag | Phase 3 | Chemotherapy-Induced Thrombocytopenia | - | - |
Pyrotinib | Phase 3 | HER2-positive Breast Cancer | - | - |
Remimazolam Tosilate | Phase 3 | General Anesthesia | - | - |
capecitabine + camrelizumab + apatinib | Phase 3 | Breast Cancer | - | - |
Camrelizumab | Phase 3 | Hepatocellular Carcinoma | - | - |
Propofol | Phase 3 | Anesthesia for Elective Surgery Patients | - | - |
apatinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
SHR6390 | Phase 3 | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer | - | - |
JSKN016 Injection | Phase 3 | Triple Negative Breast Cancer | - | - |
SHR7280 tablets | Phase 3 | Uterine Fibroids With Menorrhagia | - | - |
camrelizumab combined with rivoceranib and HAIC | Phase 3 | Potentially Resectable Hepatocellular Carcinoma | - | - |
SHR-A1811 | Phase 3 | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | - | - |
Apatinib Mesylate | Phase 3 | Hepatocellular Carcinoma | - | - |
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel | Phase 3 | Breast Cancer Invasive | - | - |
SHR8554 Injection | Phase 3 | Pain | - | - |
INS068 injection | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Fuzuloparib , Abiraterone acetate and Prednisone | Phase 3 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - | - |
NALIRIFOX+Adebrelimab | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
Adebrelimab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Lenvatinib | Phase 2 | Intrahepatic Cholangiocarcinoma | - | - |
HRS-4642 | Phase 2 | Pancreatic Cancer | - | - |
Rezvilutamide | Phase 2 | Prostate Cancer | - | - |
Famitinib Malate | Phase 2 | Breast Neoplasms | - | - |
SHR-A2102 or/and HRS-4642 | Phase 2 | Pancreatic Cancer | - | - |
Taxane Chemotherapy | Phase 2 | HER2 + Breast Cancer | - | - |
HRS-4642+AG | Phase 2 | Pancreatic Cancer | - | - |
irinotecan liposome (II) + temozolomide + fluzoparib | Phase 2 | Ewing Sarcoma | - | - |
Camrelizumab plus apatinib CohortA | Phase 2 | Gestational Trophoblastic Neoplasia | - | - |
Adebrelimab combined with Apatinib | Phase 2 | SCLC | - | - |
Camrelizumanb plus TPF | Phase 2 | Oral Squamous Cell Carcinoma | - | - |
Apatinib+IE | Phase 2 | Effect of Drug | - | - |
Neoadjuvant Chemotherapy | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
Bupivacaine Liposome Injection | Phase 2 | Local Analgesia Via Nerve Block | - | - |
Radiation | Phase 2 | Esophageal Neoplasms | - | - |
Fluzoparib | Phase 2 | Metastatic Castration Resistant Prostate Cancer | - | - |
Herombopag | Phase 2 | Non Severe Aplastic Anemia | - | - |
EC chemotherapy | Phase 2 | Breast Cancer Invasive | - | - |
SHR-3167 Injection | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
HRS-4508+ Capecitabine | Phase 2 | Solid Tumor | - | - |
HRS-9190 | Phase 2 | Neuromuscular Blockade | - | - |
HR19042 Capsules | Phase 2 | IgA Nephropathy | - | - |
FRSW117 | Phase 2 | Severe Hemophilia A | - | - |
HRS-4508 tablet | Phase 2 | Lung Cancer | - | - |
Famitinib | Phase 2 | Colorectal Cancer | - | - |
SHR-A1811 Injection | Phase 2 | Recurrent or Metastatic Cervical Cancer | - | - |
HS-20093 for Injection | Phase 2 | Prostate Cancer | - | - |
KN046 | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
SHR-3167 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
SHR-4394 | Phase 2 | Prostate Cancer | - | - |
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 | Phase 2 | Advanced Non-small Cell Lung Cancer | - | - |
HRS-9190; under Inhalational Anesthesia | Phase 2 | Neuromuscular Blockade | - | - |
Tegileridine Fumarate lnjection | Phase 2 | Abirritation in the ICU | - | - |
SHR4640 ；Febuxostat | Phase 2 | Primary Gout and Hyperuricemia | - | - |
Apatinib and Adebrelimab in Combination With chemotherapy | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | - | - |
SHR-1210+GEMOX | Phase 2 | Biliary Tract Cancer | - | - |
entinostat | Phase 2 | Breast Cancer | - | - |
docetaxel,0xaliplatin,capecitabine | Phase 2 | Gastric Cancer | - | - |
Camrelizumab+Fluzoparib | Phase 2 | Germline BRCA-mutated HER2-negative Breast Cancer | - | - |
Epirubicin | Phase 2 | Breast Cancer | - | - |
Camrelizumab and Apatinib Plus GP | Phase 2 | Locally Advanced Biliary Tract Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's drug pipeline?→
CatalystAlert tracks 67 drug candidates in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JHPCY) pipeline across Phase 3, Phase 2. Its lead program is SHR-1210 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's next FDA catalyst?→
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JHPCY) next tracked catalyst is a Phase 2 expected November 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JHPCY biotech catalysts?→
Add JHPCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.